Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Liver International · 2024
DOI: 10.1111/liv.15878 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, 2024. Verfasst von Liang-Jie Tang und 17 weiteren Autor:innen. Beteiligte Einrichtung: MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Hauptthemen laut MEDLINE: Complement C3, Non-alcoholic Fatty Liver Disease, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Development Fund, Macau SAR, High-Level Creative Talents from Department of Public Health in Zhejiang Province.
Abstract (Originalsprache)
Background
Metabolic dysfunction‐associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N‐terminal propeptide of collagen type 3 (PRO‐C3) is a biomarker of advanced fibrosis in MAFLD and PRO‐C3 may be involved in renal fibrosis. We aimed to use PRO‐C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease (MAFLD–CKD).
Methods
A derivation and independent validation cohort of 750 and 129 Asian patients with biopsy‐confirmed MAFLD were included. Serum PRO‐C3 concentration was measured and regression analyses were performed to examine associations with MAFLD–CKD. A derivative algorithm for MAFLD–CKD risk prediction was evaluated with receiver operator characteristic (ROC) curve analysis.
Results
The study included two Asian cohorts ( n = 180 with MAFLD–CKD; mean‐eGFR: 94.93 mL/min/1.73 m 2 ; median‐urinary albumin‐to‐creatinine ratio: 6.58 mg/mmol). PRO‐C3 was associated with the severity of MAFLD‐CKD and independently associated with MAFLD–CKD (adjusted odds ratio = 1.16, 95% confidence interval [CI]: 1.08–1.23, p < .001). A new non‐invasive score (termed PERIOD) including PRO‐C3 efficiently predicted MAFLD‐CKD (AUROC = .842, 95% CI: .805–.875). Accuracy, specificity and negative predictive values were 80.2%, 85.1% and 88.4%, respectively. In the validation cohort, the PERIOD score had good diagnostic performance (AUROC = .807, 95% CI: .691–.893) with similar results in all patient subgroups. In the MAFLD–CKD subgroup, the accuracy for identifying advanced fibrosis was further improved by combining the PRO‐C3‐based ADAPT with the Agile 3+ scores (AUROC = .90, 95% CI: .836–.964).
Conclusions
The PERIOD score is helpful for accurately predicting the risk of MAFLD–CKD. PRO‐C3 can also be used to assess liver fibrosis in people with MAFLD–CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- Cancer Center, Faculty of Health Sciences, University of Macau, Taipa, Macau SAR, China.
- Department of Nephrology, Jiangnan University Medical Center, Wuxi, China.
- Affiliated Wuxi Clinical College of Nantong University, Wuxi, China.
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
- State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
ORCID-Profile: Grace Lai-Hung Wong, Morten Karsdal, Diana Julie Leeming, Giovanni Targher, Mohammed Eslam, Vincent Wai-Sun Wong, Ming-Hua Zheng
Förderung
- National Natural Science Foundation of China
- Science and Technology Development Fund, Macau SAR
- High-Level Creative Talents from Department of Public Health in Zhejiang Province
- Ministry of Education Frontiers Science Centre for Precision Oncology, University of Macau
- The Chinese University of Hong Kong
- Southampton NIHR Biomedical Research Centre
- National Health and Medical Research Council of Australia
- Chinese University of Hong Kong
Zitieren
APA
Tang, L. J., Sun, D. Q., Song, S. J., Yip, T. C., Wong, G. L., Zhu, P. W., Chen, S. D., Karsdal, M., Leeming, D. J., Jiang, P., Wang, C., Chen, Q., Byrne, C. D., Targher, G., Eslam, M., George, J., Wong, V. W., & Zheng, M. H. (2024). Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver International. https://doi.org/10.1111/liv.15878
Vancouver
Tang LJ, Sun DQ, Song SJ, Yip TC, Wong GL, Zhu PW, et al. Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort. Liver International. 2024. doi:10.1111/liv.15878
BibTeX
@article{Tang2024,
author = {Tang, Liang-Jie and Sun, Dan-Qin and Song, Sherlot Juan and Yip, Terry Cheuk-Fung and Wong, Grace Lai-Hung and Zhu, Pei-Wu and Chen, Sui-Dan and Karsdal, Morten and Leeming, Diana Julie and Jiang, Pei and Wang, Cong and Chen, Qiang and Byrne, Christopher D and Targher, Giovanni and Eslam, Mohammed and George, Jacob and Wong, Vincent Wai-Sun and Zheng, Ming-Hua},
title = {Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort},
journal = {Liver International},
year = {2024},
doi = {10.1111/liv.15878}
}
EUVIMED